Cemex S.A.B. de C.V. Sponsored ADR vs Quest Diagnostics Inc — how do they compare? Cemex S.A.B. de C.V. Sponsored ADR trades at $9.56 (market cap $13.79B), while Quest Diagnostics Inc trades at $230.97 (market cap $25.48B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals — on Pluang, investors hold Cemex S.A.B. de C.V. Sponsored ADR for 1 Days and Quest Diagnostics Inc for 56 Days on average.
| CX | DGX | |
|---|---|---|
Market Cap | $13.79B | $25.48B |
Volume | 3,993,982 | 941,866 |
Sector | Basic Materials | Health |
52-Week High | $13.55 | $247.45 |
52-Week Low | $9.15 | $173.49 |
Typical Hold Time | 1 Days | 56 Days |
Enterprise Value | $19.79B | $31.23B |
Dividend Yield | 1.3% | 1.49% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
Trailing returns across standard periods
Cemex produces, distributes, markets, and sells cement, ready-mix concrete, aggregates, and other construction materials. Its operations serve markets around the world.
Read more on CX →Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →